May 24, 2022 – Vtama® (tapinarof) 1% cream has been approved to treat plaque psoriasis in adults. Vtama is the first novel topical treatment for plaque psoriasis to receive FDA
May 23, 2022 – Teva Pharmaceuticals has recalled one lot of Anagrelide Capsules, USP 0.5mg, due to dissolution failure during routine stability testing.
May 20, 2022 – Vidaza® (azacytidine) is now approved to treat newly diagnosed juvenile myelomonocytic
leukemia (JMML), a rare form of blood cancer, in pediatric patients
May 19, 2022 – Tpoxx® (tecovirimat – SIGA Technologies) has received an expanded smallpox treatment
indication, as well as FDA approval of a new dosage formulation
May 13, 2022 – Dupixent® (tirzepatide) has become the first drug to win FDA approval specifically for treating eosinophilic esophagitis (EoE). It is indicated to treat EoE
May 13, 2022 – Eli Lilly’s MounjaroTM (tirzepatide) has received FDA approval for use alongside diet and exercise to improve blood sugar control in adults who have type 2 diabetes.